ABL fusion oncogene transformation and inhibitor sensitivity are mediated by the cellular regulator RIN1

[1]  G. Superti-Furga,et al.  BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib. , 2010, Blood.

[2]  T. Phang,et al.  Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl. , 2010, Cancer cell.

[3]  K. Martin,et al.  Regulated expression of the Ras effector Rin1 in forebrain neurons , 2010, Molecular and Cellular Neuroscience.

[4]  T. Clackson,et al.  AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. , 2009, Cancer cell.

[5]  M. Lieber,et al.  The B cell mutator AID promotes B lymphoid blast crisis and drug resistance in chronic myeloid leukemia. , 2009, Cancer cell.

[6]  Zhifu Sun,et al.  Cell Proliferation and Epidermal Growth Factor Signaling in Non-small Cell Lung Adenocarcinoma Cell Lines Are Dependent on Rin1 , 2009, The Journal of Biological Chemistry.

[7]  A. Koleske,et al.  Enhancement of ABL Kinase Catalytic Efficiency by a Direct Binding Regulator Is Independent of Other Regulatory Mechanisms* , 2008, Journal of Biological Chemistry.

[8]  T. Smithgall,et al.  Tyrosine phosphorylation in the SH3 domain disrupts negative regulatory interactions within the c-Abl kinase core. , 2008, Journal of molecular biology.

[9]  M. Warmuth,et al.  Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. , 2008, Cancer cell.

[10]  Q. Lin,et al.  Disruption of the Bcr-Abl/Hsp90 protein complex: a possible mechanism to inhibit Bcr-Abl-positive human leukemic blasts by novobiocin , 2008, Leukemia.

[11]  J. Colicelli,et al.  Integration of Transforming Growth Factor β and RAS Signaling Silences a RAB5 Guanine Nucleotide Exchange Factor and Enhances Growth Factor-Directed Cell Migration , 2007, Molecular and Cellular Biology.

[12]  S. Dry,et al.  RIN1 is a breast tumor suppressor gene. , 2007, Cancer research.

[13]  D. Kufe,et al.  MUC1 oncoprotein regulates Bcr-Abl stability and pathogenesis in chronic myelogenous leukemia cells. , 2007, Cancer research.

[14]  C. Sawyers,et al.  Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. , 2007, The Journal of clinical investigation.

[15]  D. Johnson,et al.  Signal transduction pathways that contribute to myeloid differentiation , 2007, Leukemia.

[16]  T. Graeber,et al.  Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants , 2006, Proceedings of the National Academy of Sciences.

[17]  W. Plunkett,et al.  A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia. , 2006, Cancer research.

[18]  Oliver Hantschel,et al.  Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase. , 2006, Molecular cell.

[19]  J. Colicelli,et al.  RIN1 Is an ABL Tyrosine Kinase Activator and a Regulator of Epithelial-Cell Adhesion and Migration , 2005, Current Biology.

[20]  B. Druker,et al.  Oncogenes and Tumor Suppressors (795 articles) , 2004 .

[21]  Andrew P. Weng,et al.  Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia , 2004, Science.

[22]  O. Witte,et al.  The BCR-ABL story: bench to bedside and back. , 2004, Annual review of immunology.

[23]  O. Witte,et al.  IL-3 receptor signaling is dispensable for BCR-ABL-induced myeloproliferative disease , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[24]  E. Dougherty,et al.  Identification of signature genes by microarray for acute myeloid leukemia without maturation and acute promyelocytic leukemia with t(15;17)(q22;q12)(PML/RARalpha). , 2003, International journal of oncology.

[25]  Philip D Stahl,et al.  The Src Homology 2 Domain of Rin1 Mediates Its Binding to the Epidermal Growth Factor Receptor and Regulates Receptor Endocytosis* , 2003, Journal of Biological Chemistry.

[26]  R. Yacobi,et al.  Autoinhibition of Bcr-Abl through Its SH3 Domain , 2003, Molecular Cell.

[27]  H. Duewel,et al.  Two Distinct Phosphorylation Pathways Have Additive Effects on Abl Family Kinase Activation , 2003, Molecular and Cellular Biology.

[28]  G. Daley,et al.  Mechanisms of Autoinhibition and STI-571/Imatinib Resistance Revealed by Mutagenesis of BCR-ABL , 2003, Cell.

[29]  G. Superti-Furga,et al.  Structural Basis for the Autoinhibition of c-Abl Tyrosine Kinase , 2003, Cell.

[30]  Alcino J. Silva,et al.  The RAS Effector RIN1 Modulates the Formation of Aversive Memories , 2003, The Journal of Neuroscience.

[31]  T. Grogan,et al.  Gene Expression Profile of Serial Samples of Transformed B-Cell Lymphomas , 2003, Laboratory Investigation.

[32]  D. Sgroi,et al.  Specific down-modulation of Notch1 signaling in cervical cancer cells is required for sustained HPV-E6/E7 expression and late steps of malignant transformation. , 2002, Genes & development.

[33]  Richard A. Flavell,et al.  Survival signaling mediated by c-Jun NH2-terminal kinase in transformed B lymphoblasts , 2002, Nature Genetics.

[34]  G. Superti-Furga,et al.  Autoinhibition of c-Abl , 2002, Cell.

[35]  G. Neubauer,et al.  Phosphorylation and structure-based functional studies reveal a positive and a negative role for the activation loop of the c-Abl tyrosine kinase , 2001, Oncogene.

[36]  P. N. Rao,et al.  Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.

[37]  J. Melo,et al.  The molecular biology of chronic myeloid leukemia. , 2000, Blood.

[38]  R. V. van Etten,et al.  c-Abl Has High Intrinsic Tyrosine Kinase Activity That Is Stimulated by Mutation of the Src Homology 3 Domain and by Autophosphorylation at Two Distinct Regulatory Tyrosines* , 2000, The Journal of Biological Chemistry.

[39]  P. Seeburg,et al.  Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. , 2000, Science.

[40]  T. Ito,et al.  A new ETV6/TEL partner gene, ARG (ABL-related gene or ABL2), identified in an AML-M3 cell line with a t(1;12)(q25;p13) translocation. , 2000, Blood.

[41]  R. Ren,et al.  Bcr-Abl with an SH3 Deletion Retains the Ability To Induce a Myeloproliferative Disease in Mice, yet c-Abl Activated by an SH3 Deletion Induces Only Lymphoid Malignancy , 1999, Molecular and Cellular Biology.

[42]  A. Kazlauskas,et al.  c-Abl is activated by growth factors and Src family kinases and has a role in the cellular response to PDGF. , 1999, Genes & development.

[43]  B. Calabretta,et al.  The SH3 domain contributes to BCR/ABL-dependent leukemogenesis in vivo: role in adhesion, invasion, and homing. , 1998, Blood.

[44]  A. Dhaka,et al.  Regulation of the oncogenic activity of BCR-ABL by a tightly bound substrate protein RIN1. , 1997, Immunity.

[45]  T. Golub,et al.  Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia , 1996, Molecular and cellular biology.

[46]  H. Malech,et al.  Enhanced engraftment of hematopoietic progenitor cells in mice treated with granulocyte colony-stimulating factor before low-dose irradiation: implications for gene therapy. , 1996, Blood.

[47]  R. Hardy,et al.  B‐Lineage Differentiation Stages Resolved by Multiparameter Flow Cytometry , 1995 .

[48]  J. Colicelli,et al.  A human protein selected for interference with Ras function interacts directly with Ras and competes with Raf1 , 1995, Molecular and cellular biology.

[49]  O. Witte,et al.  BCR-ABL and v-abl oncogenes induce distinct patterns of thymic lymphoma involving different lymphocyte subsets , 1993, Journal of virology.

[50]  N. Rosenberg,et al.  Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[51]  O. Witte,et al.  In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[52]  T. Miyazaki,et al.  Establishment and characterization of a cell line, TOM-1, derived from a patient with Philadelphia chromosome-positive acute lymphocytic leukemia , 1987 .

[53]  Rosalind C. Lee,et al.  The mouse c-abl locus: Molecular cloning and characterization , 1984, Cell.

[54]  Tannishtha Reya,et al.  Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia , 2009, Nature.

[55]  J. Cigudosa,et al.  Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. , 2008, Cancer cell.

[56]  L. Wiedemann,et al.  The novel activation of ABL by fusion to an ets-related gene, TEL. , 1995, Cancer research.